Effect of an insulin-like growth factor binding protein fusion protein on thymidine incorporation in neuroblastoma and rhabdomyosarcoma cell lines

Endocrinology

Volumn 145, Issue 7, 2004, Pages 3369-3374

  Dake, Brian L ^a   Boes, Mary ^b   Bach, Leon A ^c   Bar, Robert S ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; HYBRID PROTEIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 6; THYMIDINE;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; DRUG SYNTHESIS; INCUBATION TIME; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; RHABDOMYOSARCOMA; SARCOMA CELL;

ANIMALS; CATTLE; CELL DIVISION; CELL LINE, TUMOR; ENDOTHELIUM, VASCULAR; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 6; NEUROBLASTOMA; RECOMBINANT FUSION PROTEINS; RHABDOMYOSARCOMA; THYMIDINE;

EID: 3042640661     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2003-1667     Document Type: Article

References (45)

1. Jones JI, Clemmons DR 1995 Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3-34
2. Daughaday WH, Laron Z, Pertzelan A, Heins JN 1969 Defective sulfation factor generation: a possible etiological link in dwarfism. Trans Assoc Am Physicians 82:129-140
3. Monzavi R, Cohen P 2002 IGFs and IGFBPs: role in health and disease. Best Pract Res Clin Endocrinol Metab 16:433-447
4. Jadresic A, Banks LM, Child DF, Diamant I, Doyle FH, Fraser TR, Joplin GF 1982 The acromegaly syndrome - relation between clinical features, growth hormone values and radiological characteristics of the pituitary tumours. Q J Med 51:189-204
5. Linfoot JA 1981 Acromegaly and gigantism. In: Daughaday WH, ed. Endocrine control of growth. New York: Elsevier; 207-267
6. Gallicchio M, Kaun C, Wojta J, Binder B, Bach I 2003 Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro. J Cell Physiol 197:131-138
7. LeRoith D, Roberts Jr CT 2003 The insulin-like growth factor system and cancer. Cancer Lett 195:127-137
8. Butt AJ, Dickson KA, McDougall F, Baxter RC 2003 Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J Biol Chem 278:29676-29685
9. Qing RQ, Schmitt S, Ruelicke T, Stallmach T, Schoenle EJ 1996 Autocrine regulation of growth by insulin-like growth factor (IGF)-II mediated by type I IGF-receptor in Wilms tumor cells. Pediatr Res 39:160-165
10. Moschos SJ, Mantzoros CS 2002 The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 63:317-332
11. Toretsky JA, Helman LJ 1996 Involvement of IGF-II in human cancer. J Endocrinol 149:367-372
12. Grellier P, Berrebi D, Peuchmaur M, Babajko S 2002 The IGF system in neuroblastoma xenografts: focus on IGF-binding protein 6. J Endocrinol 172:467-476
13. Kiess W, Koepf G, Christiansen H, Blum WF 1997 Human neuroblastoma cells use either insulin-like growth factor-I or insulin-like growth factor-II in an autocrine pathway via the IGF-I receptor: variability of IGF, IGF binding protein (IGFBP) and IGF receptor gene expression and IGF and IGFBP secretion in human neuroblastoma cells in relation to cellular proliferation. Regul Pept 72:19-29
14. Schmitt S, Ren-Qui Q, Torresani T, Doebeli M, Zapf J, Schoenle EJ 1997 High molecular weight forms of IGF-II ('big-IGF-II') released by Wilms' tumor cells. Eur J Endocrinol 137:396-401
15. Minniti CP, Kohn EC, Grubb JH, Sly WS, Oh Y, Muller HL, Rosenfeld RG, Helman LJ 1992 The insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor mediates IGF-II-induced motility in human rhabdomyosarcoma cells. J Biol Chem 267:9000-9004
16. El-Badry OM, Minniti C, Kohn EC, Houghton PJ, Daughaday WH, Helman LJ 1990 Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ 1:325-331
17. Nielsen FC, Haselbacher G, Christiansen J, Lake M, Gronborg M, Gammeltoft S 1993 Biosynthesis of 10 kDa and 7.5 kDa insulin-like growth factor II in a human rhabdomyosarcoma cell line. Mol Cell Endocrinol 93:87-95
18. Gallicchio MA, Kneen M, Hall C, Scott AM, Bach LA 2001 Overexpression of insulin-like growth factor binding protein-6 inhibits rhabdomyosarcoma growth in vivo. Int J Cancer 94:645-651
19. Bach LA, Hsieh S, Brown AL, Rechler MM 1994 Recombinant human insulin-like growth factor binding protein-6 inhibits IGF-II-induced differentiation of L6A1 myoblasts. Endocrinology 135:2168-2176
20. Seurin D, Lassarre C, Bienvenu G, Babajko S 2002 Insulin-like growth factor binding protein-6 inhibits neuroblastoma cell proliferation and tumour development. Eur J Cancer 38:2058-2065
21. Grellier P, DeGalle B, Babjko S 1998 Expression of insulin-like growth factor-binding protein 6 complementary DNA alters neuroblastoma cell growth Cancer Res 58:1670-1676
22. Sueoka N, Lee H-Y, Wiehle S, Cristiano RJ, Fang BL, Ji L, Roth JA, Hong WK, Cohen P, Kurie JM 2000 Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells. Oncogene 19:4432-4436
23. Knudtson KL, Boes M, Sandra A, Dake BL, Booth BA, Bar RS 2001 Distribution of chimeric IGFBP-3 and IGFBP-4 in the rat heart: importance of C-terminal basic region. Endocrinology 142:3749-3755
24. Bar RS, Dolash S, Dake BL, Boes M 1986 Cultured capillary endothelial cells from Bovine adipose tissue: a model for insulin binding and action in microvascular endothelium. Metabolism 35:317-322
25. Booth BA, Boes M, Andress DL, Dake BL, Kiefer MC, Maack C, Linhardt RJ, Bar K, Caldwell EED, Weiler J, Bar RS 1995 IGFBP-3 and IGFBP-5 association with endothelial cells: role of C-terminal heparin binding domain. Growth Regul 15:1-17
26. Babajko S, Leneuve P, Loret C, Binoux M 1997 IGF-binding protein-6 is involved in growth inhibition in SH-SY5Y human neuroblastoma cells: its production is both IGF- and cell density-dependent. J Endocrinol 152:221-227
27. Bach LA 1999 Insulin-like growth factor binding protein-6: the 'forgotten' binding protein? Horm Metab Res 31:226-234
28. Butt AJ, Firth SM, Baxter RC 1999 The IGF axis and programmed cell death. Immunol Cell Biol 77:256-262
29. Rajah R, Valentinis B, Cohen P 1997 Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 272:12181-12188
30. Butt AJ, Firth SM, King MA, Baxter, RC 2000 Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem 275:39174-39181
31. Yee D 2002 The insulin-like growth factor system as a treatment target in breast cancer. Semin Oncol 29:86-95
32. Krajcik RA, Borofsky ND, Massardo S, Orentrich N 2002 Insulin-like growth factor I (IGF-I), IGF-binding proteins and breast cancer. Cancer Epidemiol Biomarkers Prev 11:1566-1573
33. Chen Z, Ge Y, Landman N, Kang JX 2002 Decreased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor promotes growth of human breast cancer cells. BMC Cancer 2:18-26
34. Guo N, Ye J-J, Liang S-J, Mineo R, Li S-L, Giannini S, Plymate SR, Sikes RA, Fujita-Yamaguchi Y 2003 The role of insulin-like growth factor-II in cancer growth and progression evidenced by the use of ribozymes and prostate cancer progression models. Growth Horm IGF Res 13:44-53
35. Kim EJ, Schaffer BS, Kang Y-H, MacDonald RG, Park JH 2002 Insulin-like growth factor and colon cancer proliferation: decreased production of insulin-like growth factor-binding protein (IGFBP)-6 by transfecrion of colon cancer cells with an antisense IGFBP-6 cDNA construct leads to stimulation of cell proliferation. J Gastroenterol Hepatol 17:563-570
36. Hoeflich A, Yang Y, Rascher W, Blum WF, Huber S, Koepf G, Kolb HJ, Kies W 1996 Coordinate expression of insulin-like growth factor II (IGF-II) and IGF-II/mannose-6-phosphate receptor mRNA and stable expression of IGF-I receptor mRNA during differentiation of human colon carcinoma cells (Caco-2). Eur J Endocrinol 135:49-59
37. DiPopolo A, Memoli A, Apicella A, Tuccillo C, di Palma A, Ricchi P, Acquaviva AM, Zarrilli R 2000 IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells. Oncogene 19:5517-5524
38. 3 analogues inhibit secretion of insulin-like growth factor II and stimulate production of insulin-like growth factor-binding protein-6 in conjunction with growth suppression of HT-29 colon cancer cells. Mol Cell Endocrinol 183:141-149
39. Singh P, Dai B, Yallampalli U, Lu X, Schroy PC 1996 Proliferation and differentiation of a human colon cancer cell line (CaCo2) is associated with significant changes in the expression and secretion of insulin-like growth factor (IGF) IGF-II and IGF binding protein-4: role of IGF-II. Endocrinology 137:1764-1774
40. Narayanan BA, Re GG 2001 IGF-II down regulation associated cell cycle arrest in colon cancer cells exposed to phenolic antioxidant ellagic acid. Anticancer Res 21:359-364
41. Ba F, Pang PKT, Benishin CG 2003 The establishment of a reliable cytotoxic system with SK-N-SH neuroblastoma cell culture. J Neurosci Methods 123:11-22
42. Wang W, Kuman P, Wang W, Epstein J, Helman L, Moore JV, Kumar S 1998 Insulin-like growth factor II and PAX3-FKHR cooperate in the oncogenesis of rhabdomyosarcoma. Cancer Res 58:4426-4433
43. Dagher R, Helman L 1999 Rhabdomyosarcoma: an overview. Oncologist 4:34-44
44. Butt AJ, Fraley KA, Firth SM, Baxter RC 2002 IGF-binding protein-3-induced growth inhibition and apoptosis do not require cell surface binding and nuclear translocation in human breast cancer cells. Endocrinology 143:2693-2699
45. Hong J, Zhang G, Dong F, Rechler MM 2002 Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells. J Biol Chem 277:10489-10497